News

Join the Men's Support Group
05/12/2014

The IMSMP is looking for new members to join the Men's Support Group. It meets every 2nd and 4th Thursday of the month from 6:00pm - 7:30pm. For more information call the department of social work at: (212) 265-8070.

AAN Special Session
05/03/2014

The study summarized in these four slides was selected for a special session at the AAN entitled “Multiple Sclerosis: Highlights in the Field”.  Of the 600+ abstracts submitted to the AAN, 35 were selected to be highlighted in this session as representative of important advances in the field. The presentation was very well received.  

American Academy of Neurology Update - Wednesday, April 30th
05/02/2014

The Tisch MS research center presented several more posters at the Philadelphia AAN meeting, including:

Cerebrospinal Fluid Mononuclear Phagocytes Are Decreased In Number and Express Less IL-10 In Multiple Sclerosis Compared To Values Seen With Normal Controls

Shivani Agarwal, Irene Jarchum, Ying Liu, Saud A. Sadiq

Summary:

We analyzed the cellular composition of the CSF of 21 MS patients and when compared to healthy controls the MS patients’ CSF had a...

more

AAN News - New MS Journal
05/01/2014

By Dr. James W. Stark

The AAN has announced the launch of an open-access, online  journal called Neurology® Neuroimmunology & Neuroinflammation. This new journal will include research on various areas of neuro-immunology, although multiple sclerosis research will be very prominently featured. We look forward to learning from and working with a journal dedicated exclusively to our subspecialty, especially one published by the premiere neurological organization in the world.

... more

American Academy of Neurology Update - Tuesday, April 29th
05/01/2014

Today’s Tisch MS Center poster presentations included:

Transient Neurologic Worsening after Initiation of Dimethyl Fumarate Therapy in Progressive Multiple Sclerosis Patients

James W Stark, Sydney Chirls, Saud Sadiq

Summary: We identified 18 patients with progressive forms of MS who experienced worsening of neurologic symptoms soon after starting the new medication called Tecfidera. All patients recovered to baseline status upon cessation of the medication. The...

more

American Academy of Neurology Update - Monday, April 28th
05/01/2014

The Tisch MS Research Center presented several posters today at the annual AAN meeting in Philadelphia. These include:

Inhibition of Hyaluronan Synthesis Protects Against EAE by Inducing CXCL12 in the CNS

Andre M. Mueller, Bo Hyung Yoon, Saud A. Sadiq

Summary: Inhibition of a molecule called hyaluronan synthesis is protective in a mouse model of MS by interfering with T-cells and reducing the movement of immune cells into the brain. 

 

Development of...

more

Recent Study on Simvastatin and Multiple Sclerosis
04/24/2014

By Dr. James W. Stark

A study was recently published in the journal, The Lancet, which examined the use of simvastatin in patients with secondary progressive multiple sclerosis (SPMS). The phase II study enrolled 140 SPMS patients and randomly assigned them to high dose simvastatin (ZocorTM) or a placebo. Importantly, patients were not on MS treatment at the time. The authors report a significant effect of simvastatin on reducing the rate of brain atrophy, as seen on MRI, throughout...

more

Copaxone New Formulation
04/11/2014

By Dr. James W. Stark

As many of you know, Teva Pharmaceuticals has launched a new formulation of their MS medication, Copaxone. This Copaxone is a higher dose of the medicine and is taken three times a week instead of daily. The actual amount of liquid has not changed, however, so there are no differences in the method of injection between the old and new formulations. Clinical trials have been completed and show equal efficacy between the two formulations. The incidence of...

more

Grand Rounds - March 26, 2014
03/27/2014

Dr. Stephen Kanter, Supervisor of Rehabilitation Services at the IMSMP, spoke at Grand Rounds this week. He discussed his approach to MS patients with balance dysfunction. The discussion of this very disabling MS symptom was constructive to all the clinicians and will be helpful in improving the multidisciplinary care of our patients. To schedule a rehabilitation evaluation, contact the main line at (212) 265-8070.

Tisch MS Research Center Launches Indiegogo Campaign
03/18/2014

To help fund and raise awareness for the Tisch MS Research Phase I Clinical Stem Cell Trial, we have launched a crowdfunding campaign on Indiegogo. Despite the fact that we have FDA and Institutional Review Board (IRB) approval, the trial still remains in critical need of funding. We are reaching out to all of our patients, supporters and friends to help raise awareness about our campaign. To the extent that you are comfortable, we would greatly appreciate you passing our campaign...

more

Pages

IMSMP

Because you deserve only the best in MS healthcare. Experience the difference.

521 West 57th Street

4th Floor

New York, NY 10019

p: 212.265.8070

f: 212.265.8194

Privacy Policy

        

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.